ILMN Illumina Inc

$ILMN 📝 Illumina, Inc. was selected to provide whole-genome sequencing services for the SG-INSIGHT study, a Phase III Singapore National Precision Medicine cohort expected to include approximately 450,000 individuals, to generate genomic and health data evidence. Market-relevant event

$ILMN -13%+ pre mkt The reaction is a classic “sell the news” on mixed results and lingering China/growth concerns, amplified by the stock’s prior strength. No other major catalysts appear to be driving the move And I'll be waiting with a basket when the time is right

$ILMN reports earnings today after the close. I’m bullish heading into the report: ILMN has beaten EPS estimates in 7 of its last 8 reports, according to Stock Meadow.

$ILMN The Valuation and Growth Disconnect . Based on your CFRA data screenshot, ILMN's projected performance creates a demanding hurdle: • The Forward P/E Profile: With a current price hovering near $289 and a consensus 2026 EPS estimate of $5.36 (and 2027 estimate of $6.10), the stock trades at 53.8x 2026 earnings and 47.3x 2027 earnings. • Growth Compression: Revenue growth is forecasted at ~6.4% to 9%. For a company trading at over 50x earnings, growth typically needs to exceed 20–25%. A forward PEG ratio well above 3.0 indicates that the market is paying a heavy premium for its dominant clinical sequencing market share rather than linear earnings expansion

$ILMN Remaining performance obligations were 933 million dollars at Sep 27, with about 76% expected to convert in the next twelve months and 14% in the twelve after that. That split is only in the 10-Q, the release does not carry it. The inventory build is mid-production too. Work in process was 434 million dollars and raw materials 319 million at Sep 27, against finished goods of just 58 million, and gross inventory rose to 811 million dollars from 697 million at year end.

$ILMN down about 13% after hours. Illumina, genomics and AI drug discovery darling, sold off with everything else tonight. red across the whole tech board

$ILMN Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.62 up 20.90% YoY • Reported revenue of $1.17B up 7.56% YoY • Illumina now expects FY2026 total revenue of $4.64B, non-GAAP operating margin of 23.6%, and non-GAAP diluted EPS of $5.40-$5.45; organic revenue growth greater than 4% and ROW organic revenue growth greater than 5% are unchanged.

$ILMN Technical Resistance Indicators • The stock is trading at $288.79, positioning it at the very top of its 52-week boundary ($94.00 – $309.345). • It has heavily stretched past its key exponential moving averages (EMA/MA lines) and sits right at the upper Bolllinger Band resistance ceiling. • Macro Catalyst Alert: Keep in mind that ILMN has its Q3 2026 Earnings Call scheduled tomorrow, October 29, 2026, at 4:30 PM EDT. Entering or holding aggressive long positions at a 50+ P/E ahead of binary earnings prints with such stretched expectations carries asymmetric downside risk

$ILMN Deep Analyst Polarization The massive spread between price targets ($113 to $320) illustrates how divided Wall Street is on ILMN's transition period: Analyst Firm Price Target Thesis Alignment High Bull Consensus (e.g., RBC, Piper) $310 - $320 Built on a durable core sequencing franchise, accelerating high-margin clinical consumables (+20%), and strong long-term oncology demand. BofA Securities $168 Represents structural skepticism. While upgraded due to stabilizing base margins, they see valuation heavily stretched given core instrument replacement headwinds. Citigroup (Sell) $113 Rooted in structural pricing deflation, macroeconomic headwinds in China, and soft academic/pharma capital expenditures squeezing core equipment sales.

$ILMN engaged long from our daily focus list on 9/24/26, using this BULL FLAG breakout price pattern. The Oct 230 calls paid out +264%